Avicanna Inc. (AVCN.TO)
- Previous Close
0.4200 - Open
0.4250 - Bid 0.3800 x --
- Ask 0.3900 x --
- Day's Range
0.3750 - 0.4350 - 52 Week Range
0.2300 - 0.6000 - Volume
54,100 - Avg. Volume
100,458 - Market Cap (intraday)
35.069M - Beta (5Y Monthly) 1.53
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1000 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
www.avicanna.com87
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AVCN.TO
Performance Overview: AVCN.TO
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVCN.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVCN.TO
Valuation Measures
Market Cap
38.76M
Enterprise Value
40.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.12
Price/Book (mrq)
--
Enterprise Value/Revenue
2.39
Enterprise Value/EBITDA
-5.45
Financial Highlights
Profitability and Income Statement
Profit Margin
-52.07%
Return on Assets (ttm)
-26.46%
Return on Equity (ttm)
-152.97%
Revenue (ttm)
16.79M
Net Income Avi to Common (ttm)
-8.74M
Diluted EPS (ttm)
-0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
477.2k
Total Debt/Equity (mrq)
22.62%
Levered Free Cash Flow (ttm)
-3.91M